NCT04278144 2025-09-15
A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors
Bolt Biotherapeutics, Inc.
Phase 1/2 Terminated
Bolt Biotherapeutics, Inc.
Mayo Clinic
Fate Therapeutics
Celgene
Presage Biosciences
MultiVir, Inc.